Trial Planned Into Digital, Home Monitoring of ALS Progression
The nonprofit EverythingALS is teaming up with several biotech companies for a study into the feasibility of monitoring amyotrophic…
Articles by Marisa Wexler, MS
3 HGF-based Therapies in the Works With Helixmith’s DART Program
Helixmith has unveiled its new multi-approach program called DART — Defeating ALS through Regenerative Therapeutics — to develop new…
Review Finds ‘No Strong Evidence’ Linking Medicines With ALS Risk
There is no compelling evidence to suggest any medication increases the risk of developing amyotrophic lateral sclerosis (ALS), according…
Early Tofersen Treatment May Help to Slow SOD1-ALS Progression
Early treatment with Biogen’s experimental therapy tofersen slows disease progression in people with amyotrophic lateral sclerosis (ALS)…
PrimeC Safe, Lowers ALS Disease Biomarkers in Phase 2 Clinical Study
PrimeC, an experimental combination treatment for amyotrophic lateral sclerosis (ALS) being developed by NeuroSense Therapeutics, was well tolerated…
AMX0035 Alters Activity of Various Genes Relevant to ALS, Study Finds
AMX0035 — Amylyx Pharmaceuticals’ experimental combination therapy for amyotrophic lateral sclerosis (ALS) now under review for approval in the U.S. —…
MicroRNA Blood Test for Early ALS Diagnosis Seen as Feasible in Clinic
The levels of five small RNA molecules, called microRNAs, inside tiny vesicles in the blood of people with amyotrophic…
Bipolar Disorder Therapy May Slow ALS Progression, Pilot Trial Reports
A treatment known as VPA-Li, a combination of lithium carbonate and valproic acid, may slow disease progression and improve quality…
FDA Committee, in Reversal, Favors AMX0035 Approval for ALS
In a reversal, an advisory committee of the U.S. Food and Drug Administration (FDA) now says that the current evidence…
Antibodies Against Viral Protein Tied to Better Survival Rate in ALS
Higher blood levels of antibodies against the viral protein HERV-K ENV are associated with a better survival rate and improved…